Star Therapeutics Announces $200 Million Private Financing to Advance Pipeline of Best-in-Disease Therapies
The financing supports a preclinical pipeline following the sale of Vega, which included Star’s Phase 3 lead program.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Financing will support Star’s next phase of growth, including advancement of current preclinical programs into the clinic and continued pipeline expansion
Financing follows Incyte’s July 2026 acquisition of Star subsidiary Vega Therapeutics for up to
Financing co-led by OrbiMed and Janus Henderson Investors, with participation from other leading healthcare investors
“Our mission is to develop best-in-disease therapies at scale for the millions of patients with diseases of significant unmet need,” said Adam Rosenthal, Ph.D., founder and chief executive officer of Star Therapeutics. “This financing marks the next phase for Star, building on our team’s track record of discovering and developing novel medicines. With an experienced team, a growing pipeline and the support of a top-tier investor base, we are well positioned to advance our current programs into the clinic and continue to add new, highly innovative programs to our pipeline in order to meaningfully improve patient outcomes.”
Across multiple companies, members of the Star team have invented four first-in-class therapies that are now in Phase 3 development or commercialized. The team has contributed to four successful acquisitions, including Vega Therapeutics, DICE Therapeutics, True North Therapeutics and iPierian. In July 2026, Incyte completed the acquisition of Star’s wholly owned subsidiary Vega Therapeutics in a transaction valued at up to
“I have worked with this team across three different companies, and have seen firsthand their ability to identify important therapeutic opportunities and translate them into medicines with the potential to make an impact for patients,” said Carl L. Gordon, Ph.D., CFA, managing partner at OrbiMed. “We believe Star has the team, scientific approach and pipeline to build on those achievements in its next phase of growth.”
“Star stood out to us because of the strength of its team and its proven ability to invent and develop innovative therapies,” said Vish Sridharan, M.D., assistant portfolio manager and research analyst at Janus Henderson Investors, who is joining as a board observer for Star Therapeutics. “We do not often invest in companies at this stage of development, which reflects our conviction in Star’s ability to repeatedly identify areas of significant unmet need and develop differentiated therapies to address them. We look forward to supporting the team as it advances its growing pipeline into the clinic and continues to develop the next generation of therapies for patients.”
About Star Therapeutics
Star Therapeutics is a biotechnology company focused on the discovery and development of life-changing therapies for diseases with significant unmet need. Star Therapeutics’ team has invented four first-in-class antibody therapies, including the first approved drug (Enjaymo®) for cold agglutinin disease, and three other therapies that are each in Phase 3 development. For more information, please visit Star-Therapeutics.com and follow us on LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261022642359/en/
Media:
1AB
Katie Engleman
katie@1abmedia.com
Investors:
Star Therapeutics
Scott Robertson
scott@star-therapeutics.com
Source: Star Therapeutics